Clinical development of mGluR5 Antagonists to Treat Fragile X Syndrome and Autism
Randy Carpenter, MD
Principal Investigator
with Mark Bear, PhD, MIT
Co-Investigator (2007)
Seaside Therapeutics received a major grant from the NIH, with additional funding from FRAXA and Cure Autism Now (CAN) to develop STX107, a selective mGluR5 antagonist, as a treatment for Fragile X.
Unfortunately Seaside has since discontinued development of STX107.
